Posted on April 7, 2009 at 1:14 PM
Filed under: Acquisitions | Best Practices | Careers | Case Studies | Corporate Strategy | Integration | Movers & Shakers | People
Tagged: Frank D'Amelio , Jeff Kindler , Martin Mackay , Mikael Dolsten , Pfizer , Wyeth

[ Share ]  [ E-mail ]  [ Leave a Comment ]

After Pfizer Inc. (NYSE:PFE) completes its $68 billion acquisition of Wyeth in the third quarter, it will retain eight senior executives from Wyeth and create two distinct research organizations to capitalize on their respective strengths in pharma and biotech.

A Wall Street Journal report points out that previous Pfizer deals have resulted in years of stalled research efforts. But Martin Mackay, who leads global research and development for Pfizer, thinks Pfizer is better prepared for this integration.

Mackay will lead the pharma-therapeutics research group, which focuses on traditional pharmaceuticals. Mikael Dolsten, who is president of Wyeth research, will lead the bio-therapeutics research group, which covers so-called "large-molecule research," including vaccines. Both executives will report to Pfizer CEO Jeff Kindler.

Pfizer's announcement includes appointments in those divisions and mentions plans to source new technologies among other things by working with the business development team.

Chief financial officer Frank D'Amelio is leading the integration on behalf of Pfizer. - Baz Hiralal

Go to the Pfizer integration announcement
Go to the story



Join Corporate Dealmaker's LinkedIn forum

Also From Corporate Dealmaker

• Deal Economy 2010: Morgan Stanley's Smith Barney integration
• JDA waits out storm for i2 buy
• Deal Economy 2010: Cisco's Hooper on M&A strategy
• GlobalLogic adds seasoned dealmaker
• Dell drives in IT services as PC slump deepens

Corporate Dealmaker Home Page

From TheDeal.com

• Tesla ready to drive to public market?
• Deal Economy 2010: IBM's Mendoza on using i-bankers
• Deal Economy 2010: Morgan Stanley's Smith Barney integration
• Peet's raises ante for Diedrich
• Deal Economy 2010: Cisco's Hooper on M&A strategy

TheDeal.com Home

Post a comment

Name:

Email Address:

URL:

Remember personal info?

Comments: (you may use HTML tags for style)

Please only click "Post" once. It may take a few moments to process.